Xu C - Search Results

1

Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.

Song Z, Lv D, Chen SQ, Huang J, Li Y, Ying S, Wu X, Hua F, Wang W, Xu C, Bei T, Gao C, Sun Z, Zhang Y, Lu S. Song Z, et al. Among authors: xu c. Clin Cancer Res. 2022 Feb 1;28(3):461-467. doi: 10.1158/1078-0432.CCR-21-2936. Epub 2021 Nov 9. Clin Cancer Res. 2022. PMID: 34753778 Clinical Trial.

2

A comparison of consistency of detecting BRAF gene mutations in peripheral blood and tumor tissue of nonsmall-cell lung cancer patients.

Fang M, Xu C, Wu J, Zhang Y, He C. Fang M, et al. Among authors: xu c. J Cancer Res Ther. 2014 Nov;10 Suppl:C150-4. doi: 10.4103/0973-1482.145847. J Cancer Res Ther. 2014. PMID: 25450274 Free article.

3

A comparison of consistency of detecting c-MET gene amplification in peripheral blood and tumor tissue of nonsmall cell lung cancer patients.

Chen D, Xu C, Wu J, Zhang Y, Fang M. Chen D, et al. Among authors: xu c. J Cancer Res Ther. 2015 Aug;11 Suppl 1:C63-7. doi: 10.4103/0973-1482.163843. J Cancer Res Ther. 2015. PMID: 26323927 Free article.

4

Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer.

Xu CW, Wang WX, Wu MJ, Zhu YC, Zhuang W, Lin G, Du KQ, Huang YJ, Chen YP, Chen G, Fang MY. Xu CW, et al. Thorac Cancer. 2017 Sep;8(5):417-422. doi: 10.1111/1759-7714.12455. Epub 2017 Jun 7. Thorac Cancer. 2017. PMID: 28590585 Free PMC article.

5

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report.

Zhu YC, Liao XH, Wang WX, Xu CW, Zhuang W, Zhong LH, Du KQ, Chen YP, Chen G, Fang MY. Zhu YC, et al. Onco Targets Ther. 2017 Jun 27;10:3187-3192. doi: 10.2147/OTT.S139718. eCollection 2017. Onco Targets Ther. 2017. PMID: 28721068 Free PMC article.

6

Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.

Xu CW, Wang WX, Huang RF, He C, Liao XH, Zhu YC, Du KQ, Zhuang W, Chen YP, Chen G, Fang MY. Xu CW, et al. Thorac Cancer. 2017 Nov;8(6):714-719. doi: 10.1111/1759-7714.12496. Epub 2017 Aug 28. Thorac Cancer. 2017. PMID: 28845578 Free PMC article.

7

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.

Zhu YC, Lin XP, Li XF, Wu LX, Chen HF, Wang WX, Xu CW, Shen JF, Wei JG, Du KQ. Zhu YC, et al. Thorac Cancer. 2018 Jan;9(1):159-163. doi: 10.1111/1759-7714.12518. Epub 2017 Oct 3. Thorac Cancer. 2018. PMID: 28971587 Free PMC article.

8

Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.

Zhu YC, Liao XH, Wang WX, Xu CW, Zhuang W, Wei JG, Du KQ. Zhu YC, et al. Thorac Cancer. 2018 Feb;9(2):324-327. doi: 10.1111/1759-7714.12578. Epub 2017 Dec 18. Thorac Cancer. 2018. PMID: 29251824 Free PMC article.

9

EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.

Zhu YC, Wang WX, Xu CW, Song ZB, Du KQ, Chen G, Lv TF, Song Y. Zhu YC, et al. Lung Cancer. 2018 Jan;115:131-134. doi: 10.1016/j.lungcan.2017.12.001. Epub 2017 Dec 5. Lung Cancer. 2018. PMID: 29290255

10

CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.

Zhu YC, Zhou YF, Wang WX, Xu CW, Zhuang W, Du KQ, Chen G. Zhu YC, et al. Thorac Cancer. 2018 May;9(5):652-655. doi: 10.1111/1759-7714.12617. Epub 2018 Mar 8. Thorac Cancer. 2018. PMID: 29517860 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26,523 results

Search Page

Filters